ClinicalTrials.gg
CompletedNCT01980589CHAMPION 2Updated May 30, 2017Results posted

A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects

A Phase 1 interventional study of Carfilzomib and Cyclophosphamide in Multiple Myeloma, sponsored by Amgen. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-30.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 113 studies testing carfilzomib in Multiple Myeloma — 14 open to participants now, 39 under way, 7 of them phase 3. carfilzomib · Multiple Myeloma.

Enrollment
90th of 113
22 · median 54
Started
2013
with 13 others
Phase 1
17 of 113
2 open now
Registered
42nd of 113
by date
Lead sponsor
21 of 113
Amgen

Among the 113 studies testing carfilzomib in Multiple Myeloma, this one is the 90th largest by enrollment, is one of 14 that started in 2013, is one of 17 in phase 1, and was the 42nd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

14 of the 113 studies testing carfilzomib in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About carfilzomib

carfilzomib: first FDA approval 2012 (KYPROLIS), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing carfilzomib in Multiple Myeloma, or all of them as a file.
02

Study summary

The primary objective was to determine the maximum tolerated dose of carfilzomib given twice weekly in combination with cyclophosphamide and dexamethasone for patients with newly diagnosed multiple myeloma.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • multiple myeloma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Newly diagnosed multiple myeloma
  2. , as defined by 1 or more of the following

    • Serum M-protein ≥ 0.5 g/dL, or
    • Urine M-protein ≥ 200 mg/24 hours, or
    • In subjects without detectable serum or urine M-protein, serum free light chain (SFLC) > 100 mg/L (involved light chain) and an abnormal kappa lambda ( κ/λ) ratio
  3. Males and females ≥ 18 years of age
  4. (ECOG) performance status 0-2
  5. Adequate hepatic function
  6. (LVEF) ≥ 40%
  7. (ANC) ≥ 1.0 × 10\^9/L
  8. count ≥ 50 × 10\^9/L
  9. Calculated or measured (CrCl) of ≥ 15 mL/min

Exclusion criteria

Exclusion Criteria:

  1. Planned hematopoietic stem cell transplantation (HSCT) for the initial therapy of newly diagnosed multiple myeloma
  2. Multiple myeloma of immunoglobulin M (IgM) subtype
  3. Prior systemic treatment for multiple myeloma
  4. therapy within 14 days prior to enrollment that equals or exceeds the equivalent of dexamethasone 160 mg
  5. Known amyloidosis
  6. Active congestive heart failure ( [NYHA] Class III to IV), symptomatic ischemia, or conduction abnormalities uncontrolled by conventional intervention. Myocardial infarction within 6 months prior to enrollment.
  7. Known (HIV) seropositive, infection, and/or (subjects with hepatitis B surface antigen [SAg] or core antibody receiving and responding to antiviral therapy directed at hepatitis B are allowed)
  8. Significant neuropathy (Grades ≥ 2) within 14 days prior to enrollment
  9. Any other medical disease or condition that, in the investigator's opinion, may interfere with protocol adherence or a subject's ability to give
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Carfilzomib, Cyclophosphamide and Dexamethasone (CCd)

    Participants received carfilzomib, cyclophosphamide and dexamethasone for up to eight 28-day cycles, or until progressive disease (PD), unacceptable toxicity, withdrawal of consent, or death.

    Drug: Carfilzomib · Drug: Cyclophosphamide · Drug: Dexamethasone

Interventions

  • Carfilzomib administered as a 30-minute intravenous (IV) infusion on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. On Days 1 and 2 of Cycle 1, all participants received carfilzomib at 20 mg/m².

    Also known as: PR-171, PR171, Kyprolis® (carfilzomib) for Injection

  • Cyclophosphamide administered orally (PO) at the dose of 300 mg/m² on Days 1, 8, and 15 of each 28-day cycle.

  • Dexamethasone administered PO or IV at 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-limiting Toxicities (DLTs)

    The MTD is defined as the highest carfilzomib dose at which fewer than 33% of participants experience a treatment-related dose-limiting toxicity (DLT) during the first 28-day cycle. The number of participants who experienced a DLT is reported. Dose-limiting toxicities are defined as any of the following carfilzomib-related adverse events: Nonhematologic: * ≥ Grade 3 non-hematological toxicity * ≥ Grade 3 acute kidney injury (creatinine \> 3 × baseline or \> 4.0 mg/dL) lasting \> 72 hours Hematologic: * Grade 4 neutropenia (absolute neutrophil count \[ANC\] \< 0.5 × 10\^9/L) lasting for \> 7 days * Febrile neutropenia (ANC \< 1.0 × 10\^9/L with a fever ≥ 38.3ºC) of any duration * Grade 4 thrombocytopenia (\< 25 × 10\^9/L) that persists for \> 14 days, despite holding treatment * Grade 3 or 4 thrombocytopenia associated with \> Grade 1 bleeding

    Time frame: First cycle treatment over 28-days

Secondary outcomes

  1. Overall Response Rate (ORR)

    Participants were evaluated for disease response and progression by the investigator according to the International Myeloma Working Group-Uniform Response Criteria (IMWG-URC). Disease response and progression assessments included serum protein electrophoresis (SPEP), urine protein electrophoresis (UPEP), serum immunofixation, serum free light chain (SFLC), bone marrow sample (including fluorescent in situ hybridization \[FISH\]), plasmacytoma evaluation, and skeletal survey. Overall response rate is defined as the percentage of participants with a best response of stringent complete response, complete response, very good partial response (VGPR), or partial response.

    Time frame: Disease response was assessed at the end of each cycle and 30 days after the last treatment; maximum treatment duration was 32 weeks.

  2. Time To Response (TTR)

    Time to response is defined as months from treatment start to first documentation of response of partial response or better. Summary of time to response includes confirmed responders of PR or better only.

    Time frame: Disease response was assessed at the end of each cycle and 30 days after the last treatment; maximum treatment duration was 32 weeks.

  3. Number of Participants With Adverse Events

    Adverse events (AEs) were graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03 and using the following scale: Grade 1 = Mild, Grade 3 = Moderate; Grade 3 = Severe, Grade 4 = Life-threatening; Grade 5 = Fatal.

    Time frame: From first dose of study drug until 30 days after last dose; median duration of treatment was 31 weeks.

07

Results

Posted Oct 31, 2016

Participant flow

This study was conducted at 9 centers in the United States.

Participant flow — Overall Study
MilestoneCarfilzomib 36 mg/m²Carfilzomib 45 mg/m²Carfilzomib 56 mg/m²
Started3316
Completed3316
Not completed000

Outcome measures

PrimaryNumber of Participants With Dose-limiting Toxicities (DLTs)

The MTD is defined as the highest carfilzomib dose at which fewer than 33% of participants experience a treatment-related dose-limiting toxicity (DLT) during the first 28-day cycle. The number of participants who experienced a DLT is reported. Dose-limiting toxicities are defined as any of the following carfilzomib-related adverse events: Nonhematologic: * ≥ Grade 3 non-hematological toxicity * ≥ Grade 3 acute kidney injury (creatinine \> 3 × baseline or \> 4.0 mg/dL) lasting \> 72 hours Hematologic: * Grade 4 neutropenia (absolute neutrophil count \[ANC\] \< 0.5 × 10\^9/L) lasting for \> 7 days * Febrile neutropenia (ANC \< 1.0 × 10\^9/L with a fever ≥ 38.3ºC) of any duration * Grade 4 thrombocytopenia (\< 25 × 10\^9/L) that persists for \> 14 days, despite holding treatment * Grade 3 or 4 thrombocytopenia associated with \> Grade 1 bleeding

Time frame:
First cycle treatment over 28-days
Reported as:
Number · participants
Number of Participants With Dose-limiting Toxicities (DLTs)
participantsCarfilzomib 36 mg/m²Carfilzomib 45 mg/m²Carfilzomib 56 mg/m²
Number of Participants With Dose-limiting Toxicities (DLTs)000
SecondaryOverall Response Rate (ORR)

Participants were evaluated for disease response and progression by the investigator according to the International Myeloma Working Group-Uniform Response Criteria (IMWG-URC). Disease response and progression assessments included serum protein electrophoresis (SPEP), urine protein electrophoresis (UPEP), serum immunofixation, serum free light chain (SFLC), bone marrow sample (including fluorescent in situ hybridization \[FISH\]), plasmacytoma evaluation, and skeletal survey. Overall response rate is defined as the percentage of participants with a best response of stringent complete response, complete response, very good partial response (VGPR), or partial response.

Time frame:
Disease response was assessed at the end of each cycle and 30 days after the last treatment; maximum treatment duration was 32 weeks.
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsCarfilzomib 36 mg/m²Carfilzomib 45 mg/m²Carfilzomib 56 mg/m²
Overall Response Rate (ORR)66.7 (9.4 to 99.2)100.0 (29.2 to 100.0)87.5 (61.7 to 98.4)
SecondaryTime To Response (TTR)

Time to response is defined as months from treatment start to first documentation of response of partial response or better. Summary of time to response includes confirmed responders of PR or better only.

Time frame:
Disease response was assessed at the end of each cycle and 30 days after the last treatment; maximum treatment duration was 32 weeks.
Reported as:
Median · months
Time To Response (TTR)
monthsCarfilzomib 36 mg/m²Carfilzomib 45 mg/m²Carfilzomib 56 mg/m²
Time To Response (TTR)1.3 (1.0 to 1.6)0.8 (0.7 to 1.9)1.0 (0.9 to 2.8)
SecondaryNumber of Participants With Adverse Events

Adverse events (AEs) were graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03 and using the following scale: Grade 1 = Mild, Grade 3 = Moderate; Grade 3 = Severe, Grade 4 = Life-threatening; Grade 5 = Fatal.

Time frame:
From first dose of study drug until 30 days after last dose; median duration of treatment was 31 weeks.
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsCarfilzomib 36 mg/m²Carfilzomib 45 mg/m²Carfilzomib 56 mg/m²
Any adverse event3316
Adverse event ≥ Grade 33310
Serious adverse events015
AE leading to discontinuation of study drug014
Fatal adverse events010

Adverse events

Collected over From the first dose of study medication until 30 days after the last dose; median duration of treatment was 31 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Carfilzomib 36 mg/m²—0/3 (0%)3/3 (100%)
Carfilzomib 45 mg/m²—1/3 (33.3%)3/3 (100%)
Carfilzomib 56 mg/m²—5/16 (31.3%)16/16 (100%)
Most frequent serious events
Most frequent serious events
EventCarfilzomib 36 mg/m²Carfilzomib 45 mg/m²Carfilzomib 56 mg/m²
Coronary artery occlusionCardiac disorders0/31/30/16
Acute kidney injuryRenal and urinary disorders0/30/32/16
PyrexiaGeneral disorders0/30/31/16
SepsisInfections and infestations0/30/31/16
Urinary tract infectionInfections and infestations0/30/31/16
DehydrationMetabolism and nutrition disorders0/30/31/16
HypoglycaemiaMetabolism and nutrition disorders0/30/31/16
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders0/30/31/16
Most frequent other events
Showing 10 of 180
Most frequent other events
EventCarfilzomib 36 mg/m²Carfilzomib 45 mg/m²Carfilzomib 56 mg/m²
NauseaGastrointestinal disorders2/33/311/16
DyspnoeaRespiratory, thoracic and mediastinal disorders3/31/32/16
PalpitationsCardiac disorders2/30/32/16
VomitingGastrointestinal disorders1/32/36/16
HypokalaemiaMetabolism and nutrition disorders2/30/35/16
Back painMusculoskeletal and connective tissue disorders2/31/34/16
Musculoskeletal stiffnessMusculoskeletal and connective tissue disorders0/32/30/16
Pain in extremityMusculoskeletal and connective tissue disorders2/30/35/16
HeadacheNervous system disorders0/32/37/16
DepressionPsychiatric disorders2/30/30/16

Baseline characteristics

Age, Continuous
Age, Continuous(years)Carfilzomib 36 mg/m²Carfilzomib 45 mg/m²Carfilzomib 56 mg/m²Total
Median56.0 (53 to 71)63.0 (61 to 66)65.0 (49 to 81)62.5 (49 to 81)
Sex: Female, Male
Sex: Female, Male(Participants)Carfilzomib 36 mg/m²Carfilzomib 45 mg/m²Carfilzomib 56 mg/m²Total
Female0279
Male31913
Race
Race(participants)Carfilzomib 36 mg/m²Carfilzomib 45 mg/m²Carfilzomib 56 mg/m²Total
Asian1012
Black or African American1135
White121114
Other0011
European Cooperative Oncology Group (ECOG) Performance Status
European Cooperative Oncology Group (ECOG) Performance Status(participants)Carfilzomib 36 mg/m²Carfilzomib 45 mg/m²Carfilzomib 56 mg/m²Total
0 (Fully active)1179
1 (Restrictive but ambulatory)22812
2 (Ambulatory but unable to work)0011
08

Study locations

9 sites
  • California Cancer Associates for Research and Excellence
    Encinitas, California, United States
  • James R. Berenson, MD
    West Hollywood, California, United States
  • The Oncology Institute of Hope and Innovation
    Whittier, California, United States
  • Horizon Oncology Research
    Lafayette, Indiana, United States
  • Center for Cancer and Blood Disorders
    Bethesda, Maryland, United States
  • Clinical Research Alliance
    New York, New York, United States
  • Tennessee Oncology
    Nashville, Tennessee, United States
  • Texas Oncology
    Austin, Texas, United States
  • Virginia Oncology Associates
    Norfolk, Virginia, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of Mar 2016 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2016, 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2013
First posted
Nov 11, 2013
Start
Aug 2013
Primary completionActual
Mar 2016
CompletionActual
Mar 2016
Results first posted
Oct 31, 2016
Last update
May 30, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01980589
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Nov 11, 2013
Start date
Aug 2013
Primary completion
Mar 2016
Completion
Mar 2016
Results posted
Oct 31, 2016
Last update
May 30, 2017

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carfilzomib · Cyclophosphamide · Dexamethasone

Start the discussion